COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.
СтатьяConsensus StatementНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rosano Giuseppe, Jankowska Ewa A, Ray Robin, Metra Marco, Abdelhamid Magdy, Adamopoulos Stamatis, Anker Stefan D, Bayes-Genis Antoni, Belenkov Yury, Gal Tuvia B, Böhm Michael, Chioncel Ovidiu, Cohen-Solal Alain, Farmakis Dimitrios, Filippatos Gerasimos, González Arantxa, Gustafsson Finn, Hill Loreena, Jaarsma Tiny, Jouhra Fadi, Lainscak Mitja, Lambrinou Ekaterini, Lopatin Yury, Lund Lars H, Milicic Davor, Moura Brenda, Mullens Wilfried, Piepoli Massimo F, Ponikowski Piotr, Rakisheva Amina, Ristic Arsen, Savarese Gianluigi, Seferovic Petar, Senni Michele, Thum Thomas, Tocchetti Carlo G, Van Linthout Sophie, Volterrani Maurizio, Coats Andrew J S
Аннотация
Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized treatment of HF and other comorbidities (including iron deficiency), but corrective measures should not be allowed to delay vaccination. Patients with HF who have been vaccinated against COVID-19 need to continue precautionary measures, including the use of facemasks, hand hygiene and social distancing. Knowledge on strategies preventing SARS-CoV-2 infection (including the COVID-19 vaccination) should be included in the comprehensive educational programmes delivered to patients with HF.